Polypeptide Inhibitor Targets Enterovirus 3A Protein
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for enterovirus infections, such as hand-foot-and-mouth disease, myocarditis, and herpetic angina, lack specific and effective drugs for prevention and treatment, as existing therapies do not adequately target the underlying viral mechanisms.
Innovation Solution
Development of a polypeptide inhibitor targeting the enterovirus RNA suppressing protein (ERSP), specifically nonstructural protein 3A, to inhibit viral replication by interfering with the dimerization of protein 3A and preventing the production of viral small interfering RNA, thereby leveraging the host's RNA interference mechanism to reduce viral load.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used for enterovirus infections, then treatment coverage is broad, but specific and effective antiviral activity is insufficient
Solution Approach 1:
The patent introduces a small molecule compound as an intermediary substance that specifically targets and inhibits the 3A protein of enterovirus. This compound acts as a mediator between the host's antiviral mechanisms and the viral replication process, blocking the virus's ability to suppress RNA interference without affecting other viral proteins or host cellular functions.
Solution Approach 2:
The invention changes the therapeutic parameter from broad-spectrum antiviral coverage to targeted inhibition of a specific viral protein (3A). By focusing on a conserved and essential viral protein across multiple enterovirus types, the compound achieves both specificity and broad-spectrum effectiveness against different enterovirus strains.
2Adaptability or versatility
If broad-spectrum antiviral coverage is maintained, then treatment versatility is high, but specific mechanism targeting is insufficient
Solution Approach 1:
The small molecule compound exhibits multi-functionality by effectively inhibiting the 3A protein across multiple enterovirus types (EV71, CVA16, CVB3, etc.). This universal inhibition capability allows a single compound to provide broad-spectrum coverage while maintaining precise targeting of the conserved 3A protein structure and function.
3Reliability
If specific viral mechanisms are targeted, then antiviral effectiveness is improved, but drug development complexity increases
Solution Approach 1:
The patent extracts and isolates the critical viral mechanism responsible for immune evasion - the 3A protein's RNA suppressing function. By focusing drug development efforts on this single extracted target rather than attempting to inhibit all viral proteins simultaneously, the complexity of drug development is reduced while maintaining high antiviral effectiveness.
4Reliability
If host RNA interference mechanism is leveraged, then antiviral immune response is enhanced, but viral suppression mechanisms must be overcome
Solution Approach 1:
The small molecule compound performs preliminary anti-action by blocking the 3A protein's ability to suppress RNA interference before the virus can establish its replication cycle. This preemptive inhibition of viral suppression mechanisms allows the host's innate immune response to function effectively from the outset of viral infection.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polypeptide inhibitor effectively reduces viral replication and infection, providing a new therapeutic strategy for enterovirus diseases by enhancing the host's antiviral immune response and potentially overcoming drug resistance.
Implementation Method 1
inhibit viral replication by interfering with the dimerization of protein 3A
Implementation Method 2
leveraging the host's RNA interference mechanism to reduce viral load
Implementation Method 3
the function of ERSP is inhibited by the polypeptide, and the viral nucleic acid is cut by Dicer (endoribonuclease Dicer) to produce viral small interfering RNA (vsiRNA)
Data Source
AI summary
Provided are a series of polypeptides with antiviral activity. The present invention provides a new strategy for preventing and controlling Enterovirus such as EV71, CVA16, CVA6, CVB3, and CVB5 viruses and provides a new theoretical basis for accelerating the research and development of a polypeptide small molecule drug against Enterovirus such as EV71, CVA16, CVA6, CVB3, and CVB5 viruses.